Since February 2024, a licensed version of Azathioprine 50mg/5ml oral suspension became available. Therefore, for prescriptions dispensed in February and March 2024:
- where there is an endorsement for the licensed product, then reimbursement will be based on Jayempi 10mg/ml oral suspension (Nova Laboratories Ltd)
- where there is an endorsement indicating a special was supplied, then reimbursement will be based on the Part VIIIB Drug Tariff price.
- where there is no endorsement, then pharmacy contractors will be contacted by the NHS Business Services Authority to confirm what was dispensed and will be reimbursed accordingly
An adjustment will be applied automatically for these months and will appear on the relevant Schedule of Payments.